| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
HQ-415 acts as a bioactive metal chelator, targeting transition metal ions such as copper, zinc, and iron that are implicated in neurodegenerative processes. By binding to these metal ions, it modulates their bioavailability and prevents their involvement in the generation of reactive oxygen species and the aggregation of pathological proteins like amyloid-beta and alpha-synuclein. This mechanism is central to its neuroprotective effects in cellular models.
|
|---|---|
| ln Vitro |
In vitro, HQ-415 demonstrates potent activity in neurodegeneration-related cellular models, with an effective concentration (EC50) of 15 μM. This activity is attributed to its metal-chelating properties, which help mitigate metal-induced oxidative stress and protein aggregation. Its efficacy in these models underscores its potential as a neuroprotective agent.
|
| ln Vivo |
In vivo studies have not been extensively documented for HQ-415. However, based on its structural analog clioquinol, which has demonstrated neuroprotective effects in animal models of Alzheimer's disease by reducing amyloid plaque burden and improving cognitive function, HQ-415 is expected to exhibit similar or enhanced in vivo activity due to its improved physicochemical properties.
|
| Enzyme Assay |
The metal-chelating activity of HQ-415 can be assessed using in vitro biochemical assays. A typical protocol involves incubating the compound with a metal ion, such as Cu(II) or Zn(II), and measuring the formation of a metal-ligand complex using UV-Vis spectrophotometry or fluorescence spectroscopy. The chelation efficiency and stoichiometry are determined by titration experiments, and the stability constant of the complex is calculated.
|
| Cell Assay |
The neuroprotective effects of HQ-415 are evaluated in cultured neuronal cell lines, such as SH-SY5Y or PC12 cells. Cells are pretreated with HQ-415 and then exposed to neurotoxic insults, such as hydrogen peroxide or amyloid-beta peptide. Cell viability is measured using MTT or LDH release assays, and markers of oxidative stress and apoptosis are assessed to determine the compound's protective efficacy.
|
| Animal Protocol |
The in vivo efficacy of HQ-415 can be evaluated in animal models of neurodegeneration, such as transgenic mouse models of Alzheimer's disease (e.g., APP/PS1 mice). HQ-415 is typically administered orally or intraperitoneally, and its effects on cognitive function are assessed using behavioral tests (e.g., Morris water maze). Brain tissues are then analyzed for amyloid plaque burden, metal ion levels, and oxidative stress markers.
|
| ADME/Pharmacokinetics |
As a small-molecule metal chelator with a molecular weight of 415.48 g/mol, HQ-415 is expected to have favorable drug-like properties, including the potential for oral bioavailability and blood-brain barrier penetration, which is critical for central nervous system targets. Its pharmacokinetic profile is likely similar to that of clioquinol, with moderate half-life and distribution to the brain.
|
| Toxicity/Toxicokinetics |
Based on its structural similarity to clioquinol, HQ-415 is expected to have a favorable safety profile at therapeutic doses. However, like other metal chelators, potential toxicities may include gastrointestinal disturbances and, at very high doses, systemic metal depletion. Long-term safety studies are required to fully characterize its toxicological profile.
|
| Additional Infomation |
HQ-415 is a research compound primarily used to study the role of metal ions in neurodegeneration. It is structurally related to clioquinol and serves as a valuable tool for investigating metal chelation as a therapeutic strategy for neurodegenerative diseases. It is not approved for clinical use and is intended for research purposes only.
|
| Molecular Formula |
C25H25N3O3
|
|---|---|
| Molecular Weight |
415.49
|
| Exact Mass |
415.189
|
| CAS # |
430462-93-4
|
| PubChem CID |
2907339
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
614.9±55.0 °C at 760 mmHg
|
| Flash Point |
325.7±31.5 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.663
|
| LogP |
4.47
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
31
|
| Complexity |
550
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C1C2=C(C([H])=C([H])C([H])=N2)C([H])=C([H])C=1C([H])(C1C([H])=C([H])C(=C(C=1[H])OC([H])([H])C([H])([H])[H])OC([H])([H])[H])N([H])C1C([H])=C(C([H])([H])[H])C([H])=C([H])N=1
|
| InChi Key |
ZUOOFZJZQYFZQW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H25N3O3/c1-4-31-21-15-18(8-10-20(21)30-3)23(28-22-14-16(2)11-13-26-22)19-9-7-17-6-5-12-27-24(17)25(19)29/h5-15,23,29H,4H2,1-3H3,(H,26,28)
|
| Chemical Name |
7-[(3-ethoxy-4-methoxyphenyl)-[(4-methylpyridin-2-yl)amino]methyl]quinolin-8-ol
|
| Synonyms |
HQ415; HQ 415; HQ-415
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5.6 mg/mL (~13.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4068 mL | 12.0340 mL | 24.0680 mL | |
| 5 mM | 0.4814 mL | 2.4068 mL | 4.8136 mL | |
| 10 mM | 0.2407 mL | 1.2034 mL | 2.4068 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
